How I Manage Cancer-Associated Thrombosis

In this concise review, we discuss some common clinical challenges in the management of patients with cancer-associated venous thromboembolism (VTE), a frequent complication in patients with cancer that increases morbidity and mortality. While direct oral anticoagulants (DOACs) have been established in clinical practice for anticoagulation in patients with VTE without cancer, their efficacy and safety in patients with cancer have not been assessed in randomized controlled trials until recently. The choice of the appropriate anticoagulant agent in the era of DOACs to treat patients with cancer-associated VTE is based on balancing the risk of recurrence against the risk of bleeding, and potential drug-drug interactions. However, the management of patients is challenged by special scenarios such as incidentally diagnosed pulmonary embolism and catheter-related thrombosis, and sometimes complicated by concomitant thrombocytopenia. We provide guidance for management of cancer-associated VTE in different clinical scenarios in a case-based manner and briefly review recent clinical studies and guidelines to explain our approach to management of the cases. Im Rahmen dieser Übersichtsarbeit werden einige Facetten und Herausforderungen beleuchtet, die die Behandlung von PatientInnen mit Krebs-assoziierten venösen Thromboembolien (VTE) mit sich bringt. Während für die Behandlung der VTE bei PatientInnen ohne Krebs direkte orale Antikoagulanzien (DOAK) bereits ihren Einzug in die klinische Routine gefunden haben, waren Effektivität und Sicherheit dieser Medikament Therapie der Krebs-assoziierten VTE bis kürzlich nicht durch ausreichende Evidenz gesichert. Verkompliziert wird Antikoagulation bei Personen mit einer Krebserkrankung durch ein erhöhtes VTE-Rezidiv- und Blutungsrisiko, potentielle Medikamenteninteraktionen, eine begleitende Thrombozytopenie sowie spezielle klinische Fälle wie die Katheter-assoziierten Thrombose oder eine inzidentell diagnostizierte Pulmonalembolie. Das Ziel dieser Arbeit ist es, die neueste Evidenz zu den klinischen Herausforderungen einer Krebs-assoziierten VTE Fall-basiert zusammenzufassen und damit einen Leitfaden für den klinischen Alltag zu bieten.

Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.

Peer-reviewed clinical and outcomes research relevant to medicinal leech therapy and its biology. Indexed in PubMed and verified against the NCBI record.

Узнайте, как это исследование связано с клинической практикой

More peer-reviewed studies in Клинические исследования.

• Leech Therapy for Knee Osteoarthritis — The Landmark RCT — Michalsen et al. (2003)
• Leech-Assisted Flap Salvage — Systematic Review of 277 Cases — Whitaker et al. (2012)
• Effects of hirudotherapy on liver functions, lipid profile, and insulin sensitivity in rats with metabolic syndrome — Bilden A et al. (2026)
• HIRUDOTHERAPY IN PRESBYACUZIS PRAECOX IN CLEAN-UP WORKERS AFTER THE CHORNOBYL ACCIDENT DURING THE POST-CATASTROPHE YEARS — Zabolotnyi D, Mishchanchuk N (2019)
• Wound healing potential of bark paste of Pongamia pinnata along with hirudotherapy: A case report — Balasooriya D, Karunarathna C, Uluwaduge I (2021)
• AIF-1 and RNASET2 Play Complementary Roles in the Innate Immune Response of Medicinal Leech — Baranzini N et al. (2019)
• Study on the effect of medicinal leech therapy (Hirudo medicinalis) on full-thickness excisional wound healing in the animal model — Zakian A et al. (2022)
• [Hirudo medicinalis-leech applications in plastic and reconstructive microsurgery--a literature review] — Knobloch K et al. (2007)
• The duration of rest and feeding greatly affects the re-breeding of ectoparasites: Hirudo verbana, Hirudo medicinalis and Hirudo orientalis — Aminov R, Frolov A, Aminova A (2022)
• Recombinant hirudin in clinical practice: focus on lepirudin — Greinacher A, Lubenow N (2001)

Browse all ASH-analysed research →